Curamir Therapeutics, founded in 2019 and based in Woburn, MA, is a biotechnology company focused on developing miRNA-based cancer therapeutics. The company was launched and incubated by Delos Capital, leveraging academic licensing from SUNY. Curamir's core mission is to improve patient outcomes by addressing chemoresistance and enhancing the systemic delivery of miRNA mimics through its proprietary miRNA engineering platform. The company aims to revolutionize oncology treatments with safer, more potent, and stable therapeutic options.

Notable figures associated with Curamir include Professor Jingfang Ju from the Renaissance School of Medicine at Stony Brook University, whose decade-long research underpins the company's technology. Key achievements include the development of a robust miRNA engineering platform that has shown promise in preclinical studies. Curamir's innovative approach has the potential to significantly impact the oncology field by providing new treatment avenues for patients facing resistant forms of cancer.